Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort study
- 3 November 2011
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 118 (18), 4992-4999
- https://doi.org/10.1182/blood-2011-05-357343
Abstract
To test recommended anticoagulation measures as predictors of 180-day venous thromboembolism (VTE) recurrence, we identified all Olmsted County, MN residents with incident VTE over the 14-year period of 1984-1997, and followed each case (N = 1166) forward in time for VTE recurrence. We tested the activated partial thromboplastin time (APTT), international normalized ratio (INR), and other measures of heparin and warfarin anticoagulation as predictors of VTE recurrence while controlling for baseline and time-dependent characteristics using Cox proportional hazards modeling. Overall, 1026 (88%) and 989 (85%) patients received heparin and warfarin, respectively, and 85 (8%) developed VTE recurrence. In multivariable analyses, increasing proportions of time on heparin with an APTT ≥ 0.2 anti-Xa U/mL and on warfarin with an INR ≥ 2.0 were associated with significant reductions in VTE recurrence, while the hazard with active cancer was significantly increased. Time from VTE onset to heparin start, duration of overlapping heparin and warfarin, and inferior vena cava (IVC) filter placement were not independent predictors of recurrence. At a heparin dose ≥ 30 000 U/d, the median proportion of time with an APTT ≥ 0.2 anti-Xa U/mL was 92%, suggesting that routine APTT monitoring and heparin dose adjustment may be unnecessary. In summary, lower-intensity heparin and standard-intensity warfarin anticoagulation are effective in preventing VTE recurrence.This publication has 48 references indexed in Scilit:
- Is Diabetes Mellitus an Independent Risk Factor for Venous Thromboembolism?Arteriosclerosis, Thrombosis, and Vascular Biology, 2009
- Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin timeJournal of Thrombosis and Haemostasis, 2009
- Monitoring unfractionated heparin with the aPTT: Time for a fresh lookThrombosis and Haemostasis, 2006
- Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long‐term recurrenceJournal of Thrombosis and Haemostasis, 2005
- Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.JCI Insight, 1993
- Heparin for 5 Days as Compared with 10 Days in the Initial Treatment of Proximal Venous ThrombosisThe New England Journal of Medicine, 1990
- Continuous Intravenous Heparin Compared with Intermittent Subcutaneous Heparin in the Initial Treatment of Proximal-Vein ThrombosisThe New England Journal of Medicine, 1986
- WarfarinThe New England Journal of Medicine, 1984
- Different Intensities of Oral Anticoagulant Therapy in the Treatment of Proximal-Vein ThrombosisThe New England Journal of Medicine, 1982
- Studies in Intravascular CoagulationCirculation, 1955